Physicians' Academy for Cardiovascular Education

Benefits diabetic patients with dual GIP/GLP-1 receptor agonist

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Literature - Frias JP, Bastyr EJ 3rd, Vignati L, et al. - Cell Metab. 2017 Aug 1;26(2):343-352.e2

Main results

Conclusion

In 108 T2DM patients inadequately controlled with metformin, NNC0090-2746 significantly improved glycemic control and reduced body weight, total cholesterol and leptin levels, compared with placebo. The treatment with NNC0090-2746 was generally safe and well tolerated. These data suggest that integrated GIP agonism may offer additional benefits on weight loss and total cholesterol.

References

Show references

Find this article online at Cell metab.

Share this page with your colleagues and friends: